Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma

Ashraf Z. Badros, Thea Nash, Christopher Lawrance, Brandon Tittle,Sunita Philip,Sarah Sunshine,Wuqaas Munir,Xiaoxuan Fan, Christina Ide,Djordje Atanackovic

BLOOD（2023）

引用 0|浏览1

暂无评分

摘要

Background: We hypothesize that combining Belantamab (Bel) direct tumor kill with the immune modulatory properties of cyclophosphamide (Cy) will enhance cytokine profile, cytotoxicity & phagocytosis with improved overall response rate (ORR) & manageable toxicities.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要